↓ Skip to main content

Gemcitabine for unresectable, locally advanced or metastatic bladder cancer

Overview of attention for article published in Cochrane database of systematic reviews, April 2011
Altmetric Badge

Mentioned by

facebook
1 Facebook page

Citations

dimensions_citation
18 Dimensions

Readers on

mendeley
129 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Gemcitabine for unresectable, locally advanced or metastatic bladder cancer
Published in
Cochrane database of systematic reviews, April 2011
DOI 10.1002/14651858.cd008976.pub2
Pubmed ID
Authors

Mike Shelley, Anne Cleves, Timothy J Wilt, Malcolm Mason

Abstract

The prognosis for unresectable, locally advanced or metastatic transitional cell carcinoma of the bladder is poor with most patients succumbing to their disease within 2 to 3 years. Clinical management at this stage of the disease is palliative with systemic chemotherapy the main treatment of choice. A number of cytotoxic agents have shown activity in metastatic disease including cisplatin, methotrexate, doxorubicin and vinblastine. However, response rates still need improving and toxicities may sometimes be severe, and so the search for newer agents with improved benefit-to-risk ratios is constantly being pursued. One such agent that shows promise is gemcitabine.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 129 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 <1%
Spain 1 <1%
Switzerland 1 <1%
Unknown 126 98%

Demographic breakdown

Readers by professional status Count As %
Student > Master 17 13%
Student > Ph. D. Student 14 11%
Student > Bachelor 14 11%
Student > Doctoral Student 8 6%
Other 8 6%
Other 26 20%
Unknown 42 33%
Readers by discipline Count As %
Medicine and Dentistry 57 44%
Nursing and Health Professions 7 5%
Biochemistry, Genetics and Molecular Biology 5 4%
Agricultural and Biological Sciences 4 3%
Pharmacology, Toxicology and Pharmaceutical Science 4 3%
Other 8 6%
Unknown 44 34%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 April 2011.
All research outputs
#22,830,981
of 25,457,858 outputs
Outputs from Cochrane database of systematic reviews
#11,281
of 11,842 outputs
Outputs of similar age
#113,155
of 120,465 outputs
Outputs of similar age from Cochrane database of systematic reviews
#95
of 99 outputs
Altmetric has tracked 25,457,858 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 11,842 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 38.9. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 120,465 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 99 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.